{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:43:19Z","timestamp":1790649799800,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1160,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1093\/annonc\/mdw240","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T03:50:30Z","timestamp":1466653830000},"page":"1782-1787","source":"Crossref","is-referenced-by-count":37,"title":["Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma"],"prefix":"10.1016","volume":"27","author":[{"given":"M.","family":"Simonelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.G.","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Borghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Denlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Noberasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.-Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abbattista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gallo Stampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carpentieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw240_bb0010","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1586\/14737140.2014.949246","article-title":"Hepatocellular carcinoma: systemic therapies and future perspectives","volume":"14","author":"Mikhail","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdw240_bb0015","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","article-title":"Hepatocellular carcinoma: reasons for Phase III failure and novel perspectives on trial design","volume":"20","author":"Llovet","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw240_bb0020","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1146\/annurev.biochem.67.1.753","article-title":"TGF-\u03b2 signal transduction","volume":"67","author":"Massague","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1093\/annonc\/mdw240_bb0025","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/01.RES.0000095246.40391.3B","article-title":"Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling","volume":"93","author":"Seki","year":"2003","journal-title":"Circ Res"},{"key":"10.1093\/annonc\/mdw240_bb0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-beta signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdw240_bb0035","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/81634","article-title":"Arteriovenous malformations in mice lacking activin receptor-like kinase-1","volume":"26","author":"Umess","year":"2000","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdw240_bb0040","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/hmg\/ddg050","article-title":"A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2","volume":"12","author":"Srinivasan","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1093\/annonc\/mdw240_bb0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1084\/jem.20091309","article-title":"Genetic and pharmacological targeting of activin receptor like kinase 1 impairs tumor growth and angiogenesis","volume":"207","author":"Cunha","year":"2010","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdw240_bb0050","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-13-2788","article-title":"Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?","volume":"20","author":"Bhatt","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw240_bb0055","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-10-1451","article-title":"Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies","volume":"71","author":"Hu-Lowe","year":"2011","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw240_bb0060","doi-asserted-by":"crossref","first-page":"18551","DOI":"10.1074\/jbc.M111.338103","article-title":"Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting","volume":"287","author":"van Meeteren","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdw240_bb0065","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1158\/1078-0432.CCR-15-1622","article-title":"A Phase I study of the anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962 in patients with advanced solid tumors","volume":"22","author":"Goff","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw240_bb0070","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.11031","article-title":"Phase I study (A8471004) in Asian patients of PF-03446962, a fully human mab against ALK-1 receptor involved in tumor angiogenesis: safety, pharmacokinetics (PK), and pharmacodynamics (PD)","volume":"31","author":"Lee","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw240_bb0075","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"10.1093\/annonc\/mdw240_bb0080","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw240_bb0085","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw240_bb0090","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw240_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdw240_bb0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol"},{"issue":"Suppl 4S","key":"10.1093\/annonc\/mdw240_bb0105","article-title":"Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC)","volume":"34","author":"Rimassa","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw240_bb0110","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1517\/13543784.2014.949339","article-title":"Tivantinib: critical review with a focus on hepatocellular carcinoma","volume":"23","author":"Caremoli","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1093\/annonc\/mdw240_bb0115","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1242\/jcs.061556","article-title":"BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo","volume":"123","author":"Suzuki","year":"2010","journal-title":"J Cell Sci"},{"key":"10.1093\/annonc\/mdw240_bb0120","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1182\/blood-2011-01-330142","article-title":"ALK1 as an emerging target for antiangiogenic therapy of cancer","volume":"117","author":"Cunha","year":"2011","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419358727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419358727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/9\/1782\/16698266\/mdw240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:00:57Z","timestamp":1624698057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419358727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0923753419358727"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw240","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}